Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.
Article 2011 en
Authors
EB
Evangelos Bournakis
EE
Eleni Efstathiou
AV
Andreas Varkaris
Abstract
1 min read
Time to castration resistance is an important predictor of outcome in CRPC. PSA reduction >30% predicts survival improvement following chemotherapy for CRPC regardless of chemotherapy applied.
Aurelius Omlin, Carmel Pezaro, S. Zaidi, David Lorente, Deborah Mukherji, Diletta Bianchini, Roberta Ferraldeschi, Shahneen Sandhu, David P. Dearnaley, Chris Parker, Nicholas van As, Johann S. de Bono, Gerhardt Attard
Aurelius Omlin, Carmel Pezaro, S. Zaidi, David Lorente, Deborah Mukherji, Diletta Bianchini, Roberta Ferraldeschi, Shahneen Sandhu, David P. Dearnaley, Chris Parker, Nicholas van As, Johann S. de Bono, Gerhardt Attard
Carmel Pezaro, Aurelius Omlin, Deborah Mukherji, Diletta Bianchini, Shahneen Sandhu, Amy Mulick, Gal Maier, David Olmos, Emilda Thompson, Gerhardt Attard, Johann S. de Bono
Howard I. Scher, Glenn Heller, Arturo Molina, Gerhardt Attard, Daniel C. Danila, Xiaoyu Jia, Weimin Peng, Shahneen Sandhu, David Olmos, Ruth Riisnaes, Robert G. McCormack, Tomasz Burzykowski, Thian Kheoh, Martin Fleisher, Marc Buyse, Johann S. de Bono
Rebeca Lozano, David Lorente, Isabel M. Aragón, Nuria Romero-Laorden, Paz Nombela, Joaquı́n Mateo, Alison Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llácer, Shahneen Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garcés, M.I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. López‐Casas, Elena Castro, Johann S. de Bono, David Olmos
Discussion(0)
No comments yet. Be the first to comment.